TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Neurosense Therapeutics Ltd. ( (NRSN) ) is now available.
NeuroSense Therapeutics Ltd. has reported additional clinical data from its Phase 2b PARADIGM Study, which began over three years ago. The study, conducted primarily in Israel, showed a significant survival advantage for patients treated with PrimeC compared to those receiving a placebo. Specifically, 50% of the participants on PrimeC remain alive, compared to just 7% on placebo, marking a statistically significant outcome. These findings underscore PrimeC’s potential to extend survival in ALS patients, a disease with limited treatment options. The company is continuing to analyze long-term data to support regulatory submissions, including efforts with Health Canada, as part of its global strategy.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of treatments for neurodegenerative diseases. The company’s primary product is PrimeC, which is aimed at addressing the unmet needs in the treatment of Amyotrophic Lateral Sclerosis (ALS).
Average Trading Volume: 361,053
Technical Sentiment Signal: Sell
Current Market Cap: $25.59M
See more data about NRSN stock on TipRanks’ Stock Analysis page.